NUWE
NuwellisCAI scenario view
RankAlpha Sentiment CodexPost-earnings T+1The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
AI commentary
The Q3 release offers a mixed operating read-through: stronger margins and pediatric sales but flat overall quarterly sales and ongoing funding risk. The packet's $5.03 November 12 adjusted close is a price anchor, not evidence of the post-release percentage reaction; a reliable pre-release comparison and verified analyst revisions were unavailable. Sentiment metrics are unverified, so the zero placeholders above must not be interpreted as observed neutral readings. This T+1 assessment remains cautious despite strong primary-source coverage.
Evidence flagged
No evidence quality warning is currently attached to this memo.
AI events
Q3 sales were $2.2 million, flat year over year despite 20% pediatric growth. Gross margin rose to 69.5% and operating loss narrowed 24% to $2.1 million, but Q3 console sales fell to eight from 12 a year earlier. Whether the larger year-to-date installed base produces recurring circuit sales remains the near-term test. [#SEC-8K-2026-11-12] SEC earnings exhibit
Nuwellis submitted a 510(k) seeking to extend Aquadex use to pediatric patients weighing at least five kilograms. Clearance could expand the addressable population, but neither FDA clearance nor a decision date is established. [#SEC-8K-2026-11-12] SEC earnings exhibit
The 10-Q reports $8.3 million of September-end cash, $9.3 million of operating cash used in the first nine months of 2026, and a runway only through Q2 2027 under management's plan. It explicitly anticipates needing additional capital to fund operations through year-end 2027; dilution or unfavorable financing is a material downside catalyst. [#10-Q-2026-11-12] SEC Form 10-Q
Recommendation
No formal recommendation provided.

